Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023
03 mai 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
17 avr. 2023 07h01 HE
|
Gritstone bio
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously...
Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
17 avr. 2023 07h00 HE
|
Gritstone bio
-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 avr. 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
04 avr. 2023 18h30 HE
|
Gritstone bio
EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
15 mars 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
09 mars 2023 16h05 HE
|
Gritstone bio
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals...
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023
02 mars 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
27 févr. 2023 16h06 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 févr. 2023 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...